CDR-Life Inc.’s Post

Context acquired CT-95, a potentially first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. Learn more here. https://lnkd.in/gVu_g6zw

Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0

With the advancement of two clinical trials treating KRAS G12D mutated cancers and the initiation of GLP toxicology studies for QTX3544, a G12V-preferring multi-#KRAS inhibitor, we aim to address the significant unmet need for patients with KRAS-mutated cancer beyond G12C.

Please read our paper just published in JITC. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. https://lnkd.in/eXwDBGZc  https://lnkd.in/ecqjqda3

Learn about NEXUS-01, our Phase 1 trial of an investigational #Nectin4 targeted antibody-drug conjugate in patients with advanced or metastatic #UrothelialCarcinoma or other solid tumors. Find detailed trial and enrollment information here: https://e.lilly/3VR2ns8 #CancerResearch #ClinicalTrials #ADCs #BladderCancer

🔬 Insights from ASCO 2024! Dr Nicolas Girard from the Curie Institute discusses the 4-year follow-up data from the CheckMate 816 trial. This study shows that neoadjuvant nivolumab combined with chemotherapy significantly improves event-free survival and pathological complete response rates in resectable NSCLC. Learn about the long-term benefits and future research directions. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #LungCancer #OncologyInnovation #CheckMate816 #NSCLC

At this year’s ESMO Immuno-Oncology Congress, we shared additional data from our Phase 1 clinical trial for XTX101, our tumor-activated, Fc-enhanced anti-CTLA-4, including more patients treated at our recommended Phase 2 dose of 150 mg Q6W. The data showed XTX101 continues to demonstrate limited treatment-related adverse events and additional evidence of monotherapy anti-tumor activity in late-line and IO refractory patients across a range of tumor types. ➡ Check out our poster to learn more: https://lnkd.in/g4ekxA48 #xiliotx #cancerresearch #immunooncology #ESMOImmuno23

Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions. https://lnkd.in/e92DENZZ #NSCLC #cancer #oncology

🧬🩸The new TSO 500 ctDNA version 2 is available now! It delivers faster turnaround times, greater analytical sensitivity & streamline workflow to enable #CGP of solid tumors, all from a blood sample!🧬🩸#NGS #liquidbiopsy @Illumina Watch this video

🎙 Tune in to OncologyTube.com to hear our Vice President of Clinical Development, Kellogg Parsons, MD, MHS, FACS at #SABC23, overview the applications of our lead investigational #ADC therapeutic, MBRC- 101, which targets EphA5 in advanced #solidtumors and shows promise in various cancers, including #breastcancer subtypes. Listen here: https://lnkd.in/gckw7gqW